^
4ms
RBM10 inhibits pancreatic cancer development by suppressing immune escape through PD-1 expression. (PubMed, J Cancer)
However, treatment with the JAK pathway inhibitor AZD1480 restored NK cell cytotoxicity against cancer cells. Finally, high RBM10 expression was associated with a favourable prognosis in pancreatic cancer patients, suggesting that RBM10 inhibits pancreatic cancer progression by suppressing tumour immune escape through JAK-STAT-mediated regulation of PD-1 expression in NK cells. This finding offers potential for the development of novel precision-targeted therapies in the management of pancreatic cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
JAK2 (Janus kinase 2) • PD-1 (Programmed cell death 1) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • RBM10 (RNA Binding Motif Protein 10)
|
AZD1480
6ms
DEC1 promotes breast cancer bone metastasis through transcriptional activation of CXCR4. (PubMed, J Biomed Res)
Notably, AMD3100 (a CXCR4 antagonist) partially reversed the DEC1-OE-induced upregulation of CXCR4 and associated pro-metastatic genes...Furthermore, pharmacological inhibition of AKT (LY294002) or JAK2 (AZD1480), but not ERK (PD98059), attenuated DEC1-mediated CXCR4 upregulation, although all three inhibitors mitigated DEC1-driven migration-related gene expression. Additionally, DEC1 enhanced CXCL12 secretion from mesenchymal stromal cells and osteoblasts, amplifying the CXCR4/CXCL12 axis within the bone microenvironment. Collectively, our findings demonstrate that DEC1 promotes breast cancer (BC) bone metastasis by directly transactivating CXCR4 expression, providing a molecular basis for targeting DEC1 to prevent and treat BC bone metastasis.
Journal
|
JAK2 (Janus kinase 2) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
LY294002 • AZD1480 • PD98059 • plerixafor
over1year
OTUB1 Promotes Glioblastoma Growth by Inhibiting the JAK2/STAT1 Signaling Pathway. (PubMed, J Cancer)
In addition, we added the JAK2 inhibitor AZD1480 to explore the regulation of OTUB1 for JAK2/STAT1 pathway in GBM... Our study reveals a novel mechanism by which OTUB1 inhibits the JAK2/STAT1 signaling pathway. This contributes to a better understanding of OTUB1's role in GBM and provides a potential avenue for targeted therapeutic intervention.
Journal
|
OTUB1 (OTU Deubiquitinase, Ubiquitin Aldehyde Binding 1)
|
AZD1480
over1year
V-set and immunoglobulin domain containing 4 inhibits oxidative stress, mitochondrial dysfunction, and inflammation to attenuate Parkinson's disease progression by activating the JAK2/STAT3 pathway. (PubMed, J Neuroimmunol)
VSIG4 suppresses oxidative stress, mitochondrial dysfunction, and inflammation by activating the JAK2/STAT3 pathway, which may be helpful in attenuating PD progression.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
AZD1480
almost2years
LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA Nephropathy. (PubMed, Kidney Int Rep)
JAK2 inhibitor, AZD1480 exhibited a dose-dependent inhibition of the LIF-induced Gd-IgA1 overproduction...In summary, IgAN cells exhibit LIF-mediated overproduction of Gd-IgA1 due to abnormal signaling. JAK2 inhibitors can counter these LIF-induced effects and block Gd-IgA1 synthesis in IgAN.
Preclinical • Journal
|
LIFR (LIF Receptor Subunit Alpha) • STAT1 (Signal Transducer And Activator Of Transcription 1) • LIF (LIF Interleukin 6 Family Cytokine)
|
AZD1480
over2years
High-dose radiation-resistant lung cancer cells stored many functional lipid drops through JAK2/p-STAT3/FASN pathway. (PubMed, J Cancer Res Clin Oncol)
Our studies discovered that lipids deposited in HDRR-LCCs were due to endogenous de novo fatty acids synthesis and exogenous lipids uptake. JAK2/p-TAT3/FASN could be used as promising targets for radiotherapy sensitization. Our study provided a new theoretical basis for studying the mechanism of radiation resistance in lung cancer.
Journal
|
FAS (Fas cell surface death receptor) • FASN (Fatty acid synthase)
|
AZD1480
over2years
Countering antidrug antibodies to programmed cell death-1 blockade in mouse Pten-null prostate cancer (AACR 2023)
Blocking STAT3 signaling with the JAK1/2 inhibitor AZD1480 restored PD-L1 blockade in pDCs and was associated with improved reduction of tumor burden...Our study shows that the presence of ADAs is associated with lack of antitumor responses to ant-PD-L1 blockade in a preclinical model of prostate cancer and provides additional data that will improve our understanding of ADAs against immune checkpoint inhibitors. This study also offers an approach to monitor ADA development and a platform to investigate novel approaches to target ADAs.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
|
AZD1480
3years
Hepatocellular carcinoma-derived exosomal miRNA-761 regulates the tumor microenvironment by targeting the SOCS2/JAK2/STAT3 pathway. (PubMed, World J Emerg Med)
These results demonstrated that exosomal miR-761 modulated the tumor microenvironment via SOCS2/JAK2/STAT3 pathway-dependent activation of CAFs. Our findings may inspire new strategies for HCC prevention and therapy.
Journal
|
SOCS2 (Suppressor Of Cytokine Signaling 2)
|
AZD1480 • TTI-101 oral
almost4years
Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation. (PubMed, Environ Toxicol)
IVM accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • SQSTM1 (Sequestosome 1)
|
AZD1480
almost4years
IL4Rα and IL13Rα1 Are Involved in the Development of Human Gallbladder Cancer. (PubMed, J Pers Med)
Taken together, our results suggest that IL4Rα and IL13Rα1 might be involved in the development of human gallbladder cancer cells and IL4Rα and IL13Rα1 complex/JAK2 signaling pathway could be efficient therapeutic targets for gallbladder cancer treatment.
Journal
|
IL13 (Interleukin 13) • IL4 (Interleukin 4)
|
AZD1480